Clinical Trial

Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Study acronym: FUGES032
Enrolling by Invitation Early Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the objective response rate (ORR) of Pembrolizumab combined with Lenvatinib and SOX compared with SOX alone in the treatment of patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.
Trial Details
NCT Number NCT07356466
Lead Sponsor Fujian Medical University
Conditions Gastric (Stomach) Cancer
Enrollment 100 participants
Start Date 2025-05-01
Primary Completion 2027-04-30 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-21